In addition,

financial pressure on healthcare systems has

In addition,

financial pressure on healthcare systems has encouraged trends of reducing the number of inpatients through providing efficient outpatient services such as Telehealthcare (McKinstry et al., 2009 and McLean et al., 2013). It is therefore of great interest to provide an efficient and safe patient-tailored, dose-controlling system for outpatients which can be remotely and digitally controlled by a healthcare provider. As oral tablets remain the most popular dosage form for patients, there is an increasing demand for a versatile and highly adjustable production ALK inhibitor method of tablets. Traditional methods of tablet manufacture typically require the use of large batches, multiple production steps, designated and expensive facilities and experienced operators. The high cost of this approach combined with its rigid nature rendered it less suitable a means for preparing personalized medicine (Khaled et al., 2014). Ideally, for a production method to address the new challenges of personalized medicine, it should be (i) highly adjustable,

(ii) affordable, (iii) of minimal space requirements, (iv) controllable by network and (v) safe. Several computer-controlled RAD001 ic50 3D printing approaches have been developed to produce oral tablets as an alternative to conventional tableting. The design was based on a laying powder bed followed by the deposition of a binder solution from the print-head in a multilayer three dimensional fashion (Katstra et al., 2000, Yu et al., 2009 and Yu

et al., 2007). The proposed technology provided rapid dissolving (Yu et al., 2007), extended release (Yu et al., 2009) and multi-phase delayed release patterns (Rowe et al., 2000). However, the process required a high level of powder flow control, moisture content control, and was limited by the choice of binder. Marked improvement could be achieved when considering the accuracy of dosing, aesthetic quality of the tablet and the thickness of layer deposition (Sandler et al., 2014a). More recently, a bench top 3D printer was much utilized to fabricate a bilayer tablet with immediate and extended release pattern (Khaled et al., 2014). However, the slow solidification and shrinking of the gel model affected the shape of the finished tablets. Fused deposition modelling (FDM) is a widely implemented method for 3D printing of solid objects (Lim, 2010). The expiration of patents of this technology is likely to lead to wide utilization of the 3D printing by a large number of consumers at a relatively low cost. The process uses pre-prepared thermoplastic polymeric filament (typically with a diameter of 1.75 mm) as an ‘ink’ and passes it through a high temperature nozzle where it is heated to a semi-liquid state.

The percentage inhibition activity was calculated and the results

The percentage inhibition activity was calculated and the results are given in Fig. 1, Fig. 2 and Fig. 3. IC50 value was calculated for each extract and positive control and obtained by plotting a graph by taking concentration on X-axis and % inhibition on Y-axis. The graph was extrapolated to find the Angiogenesis inhibitor concentration needed for 50%

inhibition [ Table 3 and Fig. 4]. Wistar albino rats of either sex weighing between 200 and 250 g were housed under standard environmental conditions (temperature of 22 ± 1° C with an alternating 12 h light–dark cycle and relative humidity of 60 ± 5%), one week before the start and also during the experiment as per the rules and regulations of the Institutional Ethical Committee and by animal regulatory body of the government (Regd. no: 516/01/CPCSEA). Acute toxicity studies were performed for selected

Etoposide purchase plant methanolic extracts according to the toxic classic method as per guidelines 423 prescribed by OECD,16 2001 using female albino rats. There is no LD50 and all the extracts tested are considered safe and nontoxic. Albino rats of either sex (200–250 g) were used in the study. The animals were fed with standard diet and water ad libitum two weeks before and during the experimental period. Each selected plant methanolic extract was tested at 400 mg/kg dose level. The animals were divided in to 12 groups (I–XII), each consisting of 6 animals. Group I received 5% gum acacia suspension and acts as a normal control and Group II received CCl4 at a dose of 1 ml/kg orally (p.o.) acts as negative control. Groups III–XII were treated with selected drugs (silymarin and plant extracts) for 5 days before the commencement of experiment and on day 6th of the experiment, blood samples were collected

(6th day) at 0 h in all groups and CCl4 was administered to all groups except Group I (normal control) 1 h after the administration of drugs. On 7th day blood samples were collected from all groups by retro orbital puncture, serum was separated by centrifugation and used for the estimation of blood serum parameters (SGOT, SGPT, SALP and T.BILI.) according to the standard procedures. The liver sections also dissected out subjected to histopathology studies and results Mannose-binding protein-associated serine protease are shown [ Table 4 and Table 5 and Fig. 5, Fig. 6, Fig. 7, Fig. 8, Fig. 9, Fig. 10 and Fig. 11]. All the animals were anesthetized with ethyl ether and livers were dissected specimens were cut into sections of 3–5 μm thickness using microtome and were stained with haemotoxylin and eosin and later the microscopic slides of the liver were photographed at 40X magnification.18 and 19 For the determination of significant inter group difference, each parameter was analyzed separately using one way analysis of variance (ANOVA) followed by Dunnet’s test was carried out to assess the hepatoprotective potency of different extracts of the plants. When two or more herbs are used in formulation they are known as polyherbal formulation.

Unfortunately, there is little rationale for the selection

Unfortunately, there is little rationale for the selection click here of probiotic strains; none consider

the differences in vaginal microbiota observed among women and there are few well-designed randomized placebo-controlled studies. The application of genomic technologies represent a major step toward achieving this goal. Personalized treatments could be geared toward a better appreciation of species-specific and temporal changes in microbiota. The success of the HPV vaccine (reviewed by Schiller and Lowy [115]) has re-energized the field of STI vaccine research after earlier disappointing results with HSV [116] and [117] and gonorrhea [118] and [119] vaccines. There are currently several new candidate HSV and chlamydia HTS assay vaccines in various stages of development and recent advances in the fields of immunology

and vaccine design offer hope for the development of vaccines targeting gonorrhea and syphilis [120]. To optimize vaccine responses against STIs, in addition to optimizing antigen types, formulations, adjuvants, and delivery methods [121], [122] and [123], we need a clear understanding of the interactions taking place at the mucosal surfaces. Vaccine development must take into account the differences between the systemic and mucosal immune responses, the compartmentalization of the mucosal immune responses, the unique characteristics of the reproductive tract mucosae, the role of the microbiome, Ketanserin the impact of sex hormones, and the interactions among all of these factors. We are just beginning to decipher these complex relationships. The authors have no conflicts of interest. The authors alone are responsible for the views expressed in this article and do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated. This study was supported by the National Institute of Allergy and Infectious

Diseases of the National Institutes of Health under award numbers K01-AI080974 (Brotman), U19-AI084044 (Ravel, Bavoil) and R01-AI089878 (Ghanem). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. “
“Herpes simplex virus type 2 (HSV-2) is an incurable sexually transmitted pathogen that infects over 500 million people worldwide and causes an estimated 23 million new infections annually [1]. In the United States, direct annual medical costs associated with HSV-2 are estimated to be $541 million, making it the third most costly STI after HIV-1 and human papillomavirus (HPV) [2]. HSV-2 seroprevalence ranges from 16% among 14–49 year olds in the United States [3], to >80% in areas of sub-Saharan Africa [4]. HSV-2 infection rates in heavily exposed populations are nearly 100%, suggesting universal susceptibility [5]. Seroprevalence in women is up to twice as high as men, and increases with age [3] and [6].

Further, the amount of information available varied tremendously

Further, the amount of information available varied tremendously by country

with the most information available on the processes in Australia, Canada, the UK, and the USA for which the information described was fairly comprehensive. The main limitation of this review is that only publications, reports and websites in English or French were included in the review. There is likely to be additional information available on the processes of immunization policy making at a national level published in languages other than English or French, particularly on national websites, though we were unable to determine to what extent. The assessment of the quality of information is another limitation of this study. Although the source and date of publication were documented,

LEE011 national policy making processes may have changed over time and it is unknown if the methods employed in the past remain the same today. As well, there are many varying perspectives of players involved in immunization policy development that may not have been reflected in the published literature due to the small number of publications and limited information provided. Granted the above-mentioned limitations, the lack of detailed information retrieved in print and on the web points to a need for countries to enhance dissemination of information on their immunization policy making processes. This exchange of information could help countries improve GSK1120212 their policy making processes by offering concrete examples of feasible policy making methods. Also, governments publishing their decision making processes would increase the credibility and transparency of immunization policy development. The information retrieved about the immunization policy making processes came mostly from industrialized countries [39], however, there was

information about four countries considered to be developing (Brazil, China, Papua New Guinea, and Thailand) and two countries considered to be least developed (Cambodia 4-Aminobutyrate aminotransferase and Mali). For the developing and least developed countries, the information retrieved briefly described the players involved and factors considered when making immunization policies. Overall, there was little information available about the processes of immunization policy development particularly in developing countries. The 14 countries with NITAGs for which information was retrieved in this review are all developed with the exception of Brazil. Brazil is considered a developing country by the United Nations [39], but is known for its strong public health system. Although there are presumably many NITAGs in existence, only 14 were identified in print literature and country websites and limited information about them was published. There is little published or easily accessible website information on the NITAGs outside of those in Australia, Canada, the UK, and the USA, at least in the English and French languages.

5% of eugenol oil on fresh carp, Cyprinus carpio L fillets durin

5% of eugenol oil on fresh carp, Cyprinus carpio L. fillets during storage in fish industry. 29 This breakthrough research suggests very high demand for isolation and quantification of eugenol from herbal formulations. With increasing human population food requirements and growing interest in need of animal protein sources from fishes, there is high demand for development of analytical method which can easily separate and quantify eugenol from other

plant interfering constituents, to be safely used in food preservation industry worldwide. Thus, validated RP-HPLC method demonstrated in this paper quantifies micrograms of eugenol in short span of time and is thus highly sensitive. This method will definitely aid in quantifying, separating potential anti-microbial commercial phytochemical like eugenol and provide highly reproducible data for quality control analysis in food technology related industries. In conclusion, solvent extraction methods by RP-HPLC PDA Selleckchem ZD1839 detection method was developed and validated for quantitative estimation of eugenol from Ayurvedic formulations of Caturjata Churna, Lavangadi Vati, Sitopaladi Churna, Jatiphaladi Churna and Clove oil successfully. The developed analytical chromatographic method offered adequate calibration curve/linearity, LOD, LOQ, system suitability, precision,

accuracy, solution stability, robustness method application and has been fully validated as per ICH guidelines. This method can be successfully applied for quality control of herbal medicines containing eugenol to screen toxic botanicals, microbial toxins, pesticides, fumigation, foreign organic matter, fingerprinting/marker PD-0332991 price compound for identification and standardization of botanical drugs containing eugenol. This will aid in identification of chemical constituents marker compounds such as chemical and active marker compounds that possess therapeutic activity of the herbal drug which are major constituents of plant materials, identifying herbal materials and standardize botanic preparations during all aspects of manufacturing process. Unoprostone All authors have none to declare. The authors gratefully acknowledge the technical

assistance rendered by Mandar Mhatre, Sreenath Nandakumar Nair, Varun Satose, Ashish Singh, Naresh Shejawal,Kavita Mhatre, Dipti Singh, Santosh Daval and Karan Sarvaiya in completing this project. “
“The conventional tableting method used involves first making granules and then compressing into tablets by way of direct (granule) tableting, but the need in recent years for process validation, GMP and automation of production processes has focused renewal of attention on the direct tableting, which involves few steps. Direct tableting of pharmaceutical materials is desirable to reduce the cost of production and is a modern technique in the tablet manufacturing, many processing steps are limited in direct compression and also wet granulation cannot be used with sensitive drugs.

Urease inhibitory activity of H pylori using selected CDs was de

Urease inhibitory activity of H. pylori using selected CDs was determined by measuring the urease catalyzed release of ammonia by Berthelot reaction. 20 In brief, the H. pylori cells were harvested from the BHI broth by centrifugation at 4 °C (4000 g, 5 min) and resuspended in ice-cold 0.1 M sodium phosphate buffer (pH 7.3) containing 10 mM EDTA. Cells were disrupted by sonication

(Sonics Vibra Cell model, USA), and the supernatant obtained after centrifugation at 4 °C (12,000 g, 5 min) was used as a source of enzyme for urease assay. The 96 well microtitre plate reaction mixture contained urea (2, 4, 6, 8, 10 mM), sodium phosphate buffer 30 μl and different concentration Ku-0059436 supplier of selected CDs 10, 50, 100 μg/ml [3]. After incubation for 10 min at 37 °C 0.66 N hydrogen sulphate 30 μl, sodium

tungstate 30 μl and of 30 μl Nessler’s reagent was added. Absorbance of the reaction mixture was recorded at 625 nm. The amount of ammonia produced was equivalent to the hydrolysis of urea. A high absorption value indicated high urease activity in the reaction mixture. IC50 of the urease inhibition was calculated using GraphPad Prism version 6.00. Docking studies were carried out as per our earlier PI3K Inhibitor Library supplier investigation.21 The selected CDs were docked onto the ligand binding sites of the H. pylori urease using ArgusLab 4.0.1 (Mark Thmopson and Planaria Software LLC). The X-ray crystallographic structures of the H. pylori urease (PDB ID-1E9Y) complexed with acetohydroxamic acid (ref), were downloaded online (www.rcsb.org) from the Research Collaboratory for Structural Bioinformatics (RCSB). The files were opened in ArgusLab window, the geometry, valency and hybridization of the structure were corrected. The structures of the selected CDs were drawn in working window of ArgusLab and were energy optimized using PM3 semi-empirical QM method. The optimizations were performed up to 500 iterations or an automatic

energy optimization gets converged. The active sites of the selected receptor were defined to include residues within a 3.5 Å radius of the complexed ligand. For docking we have used the ArgusLab scoring MycoClean Mycoplasma Removal Kit function AScore, Argus Dock engine, grid resolution of 0.4 Å with a flexible mode of ligand docking. The docking score was calculated as best ligand pose energy (kcal/mol) and the docked complexes were geometry optimized and were further analyzed for the hydrogen bonding. The distance (Å) between hydrogen bond forming residues was measured. The experimental values summarized for (MIC) of CDs against H. pylori are expressed as the mean ± SD. For inhibition of H. pylori urease studies the significance of the difference from the respective controls for each experimental test condition was assayed by using Student’s t test for each paired experiment. A p* value <0.05 was considered as a significant difference when compared with control. Results of the anti-H. pylori activity and MICs of the selected CDs are summarized in Table 1.

These classes of drugs interfere with different points in the vir

These classes of drugs interfere with different points in the viral life cycle, so the combination works synergistically.15 Though these combination therapies have increased survival and quality of life enormously, there are also problems associated with these

such as compliance, resistance, many interactions and serious side effects. Reverse transcriptase inhibitors act to inhibit the enzyme reverse Compound C supplier transcriptase, thus, inhibiting the transcription of viral RNA into DNA. Reverse transcriptase inhibitors are both nucleoside and nucleotide reverse transcriptase inhibitors, and the non-nucleoside reverse transcriptase inhibitors. Patil et al, isolated, from the Malaysian tree Calophyllum inophyllum and also from the giant African snail Achatina fulica which feeds on its leaves, coumarin derivatives designated as inophyllums. Two of the compounds inhibited HIV-1 RT with IC50 PCI-32765 concentration values of 38 and 130 nm respectively

and were active against HIV-1. 16 HIV-1 reverse transcriptase uses nucleotides to reverse transcribe the RNA of the virus into proviral DNA so that this proviral DNA can be inserted into the DNA of the host cell. In the cell, the nucleoside RT inhibitors are then phosphorylated into nucleotides, which are then used by reverse transcriptase to convert RNA into DNA. When reverse transcriptase uses these faulty building blocks, the development of the DNA is terminated and cellular enzymes can destroy the virus particles. Cross resistance between the Oxygenase NRTIs is possible.17 NRTIs, especially Zerit, Videx and Retrovir, are associated with lactic acidosis and hepatic steatosis.18 Nucleoside reverse transcriptase inhibitors can cause hyperlactemia by disrupting the function of the mitochondria, known as mitochondrial toxicity. NRTI’s can also cause hepatic steatosis. However, NRTIs are capable of causing a wide variety of long-term side effects, including myelotoxicity, lactic acidosis, polyneuropathy and pancreatitis. Long-term side effects

are theorized to be related to mitochondrial toxicity (Brinkman et al, 1998). Fast-replicating cells may also be inhibited by NRTIs leading to blood disorders like anemia and neutropenia. Macrocytic anemia and myopathy may occur with Zidovudine and oral ulcers with Zalcitabine and Didanoside. Abacavir can cause severe hypersensitivity reactions and is a contraindication for further treatment. Long-term side effects of the NRTIs are lipoatrophy.18 Nucleoside and nucleotide analogs have become the cornerstone of HAART (Highly Active Antiretroviral Therapy). Unfortunately, these drugs have shown to inhibit cellular polymerases, most notably mitochondrial DNA polymerase gamma. Studies of the NRTIs in enzyme assays and cell cultures demonstrate the following hierarchy of mitochondrial DNA polymerase gamma inhibition: Zalcitabine > Didanosine > Stavudine > Lamivudine > Zidovudine > Abacavir.

05 Analysis was by intention to treat Eighty consecutive

05. Analysis was by intention to treat. Eighty consecutive

individuals with chronic non-specific low back pain were screened for eligibility between September 1 2010 and June 30 2011. Sixty people satisfied these criteria, agreed to participate, and were randomised into the experimental (n = 30) or control (n = 30) group. Figure 2 depicts a flow diagram of the participant recruitment, reasons for ineligibility, and losses to follow-up. The groups had similar baseline demographic characteristics (presented in Table 1) and were comparable on the baseline application of the outcome measures (presented in the first two columns of Table 2). All participants received the taping to which they had been randomly allocated. One participant in the control group was lost to follow-up before the assessment at one week so data were unavailable. All other data were collected and analysed as intended. At the end of the study, all participants were asked if they were aware selleck chemicals llc of whether their group allocation was to the experimental or the control group. All participants confirmed that they were unaware

of their group assignment. Participants were not asked to guess the group to which they had been allocated. Group data for all outcomes for the experimental and control groups are presented in Table click here 2. Individual data are presented in Table 3 (see eAddenda for Table 3). At the end of the one-week period with the tape in situ, there were statistically significant

improvements on both of the measures of disability. The Oswestry Disability Index improved by 2 points in the experimental group but worsened by 2 points in the control group (betweengroup difference 4 points, 95% CI 2 to 6). However, the difference between the groups was not statistically significant four weeks later. Similarly, the Roland Morris Disability Questionnaire showed a significant benefit after the one-week taping period (between-group difference 1.2 points, 95% CI 0.4 to 2.0), but the difference was no longer statistically significant four weeks later. At the end of the one-week these period with the tape in situ, pain improved significantly more in the experimental group than in the control group, with a mean between-group difference of 1.1 cm (95% CI 0.3 to 1.9). This benefit was maintained four weeks later, with a mean between-group difference of 1.0 cm (95% 0.2 to 1.7). Fear of movement as measured by the Tampa Scale for Kinesophobia did not show any statistically significant difference between the groups at one week or four weeks later. The initial improvement in trunk flexion range of motion was 3 degrees greater in the experimental group, which was of borderline statistical significance (95% CI 0 to 5). This effect was not maintained four weeks later (mean between-group difference 0 degrees, 95% CI –3 to 3). Trunk muscle endurance improved significantly after the week of taping and this benefit was maintained four weeks later.

5% and 75% Triplicates of the solvent systems were prepared in g

5% and 75%. Triplicates of the solvent systems were prepared in glass vials, excess MPTS was added to the solutions and the vials were sealed to eliminate the possibility of evaporation. The samples were then vortexed (Heidolph Multi Reax, Heidolph Instruments, and Cinnaminson, NJ, USA) for 20 min and left to equilibrate at room temperature. After equilibration (determined as 1 week) an aliquot of the samples was centrifuged (Galaxy 20R, VWR International, Suwanee, GA, USA) at 5000 rpm for 5 min to ensure sedimentation this website of the excess MPTS and the drug content of the saturated solution was measured using a GC–MS method detailed in Section 2.4. Prior to GC–MS

measurements the internal standard (1 mg/ml of dibuthyl disulfide; DBDS) was added to the samples and dilution with ethanol and cylcohexanone was performed. A GC–MS method was chosen for the quantitative determination of MPTS. The system consisting of an Agilent Technologies 7890A GC with a 7683 autosampler and a 5975C VL MSD, triple-Axis detector (Agilent Technologies, Santa Clara, CA, USA). A DB-5MS column (30 m × 0.25 mm

ID, 0.25 μm film thickness; Agilent Technologies, Santa Clara, CA, USA) was used with He carrier gas at a flow rate of 1 ml/min and pressure of 7.6522 psi. The conditions for GC and MS are detailed in Table 1 and Table 2. Dielectric constant measurements were performed using a HP4285A LCR meter. The AC signal amplitude for the impedance measurement was 100 mV, and the applied frequency Fulvestrant supplier ranged from 75 kHz to 30,000 kHz in logarithmic distribution. All measurements were carried out at 20 ± 1 °C in a thermostatable cylindrical cell (originally prepared for a Radelkis OH-301 type dielectrometer) using an interface. Cyclohexane and ethanol were used as reference for determining the capacitances of the applied empty cell. The dielectric constant results are presented as values measured at 3022.2 kHz. LD50 studies were conducted using the Dixon up-and-down method with 1.0 mg/ml and 3.5 mg/ml KCN solutions, a 50 mg/ml MPTS stock solution,

and a 100 mg/ml TS solution. Male CD-1 mice (Charles River Breeding Laboratories, Inc., Wilmington, MA) weighing 18–28 g were housed Tolmetin at 21 °C and in light-controlled rooms (12-h light/dark, full-spectrum lighting cycle with no twilight), and were furnished with water and 4% Rodent Chow (Teklad HSD, Inc., CITY, WI) ad libitum. All animal procedures were conducted in accordance with the guidelines by “The Guide for the Care and Use of Laboratory Animals” (National Academic Press, 2010), accredited by AAALAC (American Association for the Assessment and Accreditation of Laboratory Animal Care, International). At the termination of the experiments, surviving animals were euthanized in accordance with the 1986 report of the AVMA Panel of Euthansia.

We believe that the development of infection models in adult zebr

We believe that the development of infection models in adult zebrafish might ultimately prove valuable for designing new therapeutic approaches and for elucidating the functions of the teleost immune system. The NLc (NanoLiposome cocktail) liposomes were prepared as previously described in Ruyra et al. [18]. Liposomal formulations were prepared by the thin film hydratation method [25] with some modifications. Briefly, DOPA, DLPC, cholesterol, cholesteryl and chol-PEG600 were dissolved in chloroform 17-AAG ic50 solutions (100 mg/ml) and mixed at the desired molar ratios (0.5:0.35:0.10:0.05). The organic solvent was then evaporated

by rotary evaporation to obtain a dry lipid film. For the preparation of the liposomes that contained a cocktail of immunostimulants the dry lipid film was hydrated with a solution containing 0.5 mg/ml poly(I:C) and 1.0 mg/ml LPS in PBS. The co-encapsulation of poly(I:C) Bioactive Compound Library datasheet and LPS was done with an immunostimulant:lipid ratio of 1:30 and 1:15, respectively. The resulting lipid suspensions were then vigorously shaken and were homogenised by means of an extruder (Lipex Biomembranes, Canada) through 2 stacked polycarbonate membranes (200 nm pore size, Avanti Polar Lipids) to finally obtain unilamellar liposomes. In all cases, non-encapsulated immunostimulants were removed from liposome preparations by ultracentrifugation at 110,000 × g for 30 min at

10 °C. Liposome integrity was checked by DLS and Cryo-TEM. The final NLc liposomes comprised 125.8 ± 6.6 nm liposomes containing both poly(I:C) and LPS (1 mg/ml liposome encapsulates 33.3 μg/ml poly(I:C) and 16.6 μg/ml LPS) and had a neutral surface charge (1.37 ± 3.58 mV). TCL The co-encapsulation efficiencies (EE) were of 22.3 ± 2.1% for LPS and of 99.6 ± 0.1% for poly(I:C). For long-term conservation, the cryoprotectant trehalose was incorporated into the procedure. The dry lipid film was hydrated with a solution containing the immunostimulants

and trehalose at a lipid/carbohydrate ratio of 1:5 (2.7%, w/v). The resulting NLc liposomes were frozen in liquid nitrogen, lyophilised (48 h at −80 °C) and finally, stored at RT for several weeks. When needed, the lyophilised samples were re-suspended in PBS and the morphology of the reconstituted NLc liposomes was assessed by Cryo-TEM (JEOL-JEM 1400, Japan). To quantify the amount of immunostimulants leaked after lyophilisation, liposomes encapsulating either poly(I:C) or LPS were prepared lyophilised and finally, stored at RT. At 0 h and 4 months, the dried liposomal cakes were resuspended with PBS and the free poly(I:C) or LPS was separately quantified as described in Ruyra et al. [18]. Adult wild type (wt) zebrafish were held in tanks with recirculating water under 14 h light/10 h dark at 28 °C. Adult rainbow trout (O. mykiss) were held in tanks under 12 h light/12 h dark at 15 °C.